[1]于婧 王敬萍.中间范围射血分数心力衰竭及其亚组研究进展[J].心血管病学进展,2021,(11):994-997.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
点击复制

中间范围射血分数心力衰竭及其亚组研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2021年11期
页码:
994-997
栏目:
综述
出版日期:
2021-11-25

文章信息/Info

Title:
Heart Failure with Mi d-Range Ejection Fraction?span>and Its Subgroups
文章编号:
202106058
作者:
于婧1 王敬萍1; 2
(1.山西医科大学,山西 太原 030001;2.山西省心血管病医院心内科,山西 太原 030024)
Author(s):
YU Jing1,WANG Jingping1,2 (1.Shanxi Medical University,Taiyuan 030001,ShanxiChina; 2.Department of Cardiology,Shanxi Cardiovascular Hospital,Taiyuan 030024,Shanxi,China)
关键词:
心力衰竭; 中间范围射血分数心力衰竭; 亚组; 异质性; 预后
Keywords:
Heart failure; Heart failure with mid-range ejection fraction; Subgroup; Heterogeneity; Prognosis
DOI:
10.16806/j.cnki.issn.1004-3934.2021.11.000
摘要:
2016年ESC急慢性心力衰竭诊断和治疗指南提出新的心力衰竭分型，正式将左室射血分数40%～49%的人群命名为中间范围射血分数心力衰竭。目前针对这一人群的循证医学证据相对不足，对于如何更好地治疗及改善预后仍存在不确定性。此外中间范围射血分数心力衰竭各亚组间具有异质性，使用单一节点的射血分数值确定分类存在一定的局限性，但相关前瞻性研究和临床试验较为匮乏。在整体基础上，更深入地探索与研究各亚组特点，有助于临床医生对中间范围射血分数心力衰竭患者制定针对性的治疗方案。
Abstract:
In 2016,the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure has proposed a new classification of heart failure,officially naming people with ejection fraction between 40% and 49% as heart failure with mid-range ejection fraction （HFmrEF）. At present,the evidence-based medicine for this population is relatively insufficient,and there is still uncertainty about how to better treat and improve the prognosis. In addition,there is heterogeneity among the subgroups of HFmrEF and the use of the ejection fraction value of a single node to determine the classification has some limits. However,related prospective studies and clinical trials are relatively inadequate. On the overall basis,more profound exploration and research of each subgroup characteristics could help clinicians to formulate targeted treatment plans

参考文献/References:

[1]Ponikowski P,Voors AA,Anker SD,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA) of the ESC[J]. Eur J Heart Fail,2016,18(8):891-975.

[2]Yancy CW,Jessup M,Bozkurt B,et al. 2013 ACCF/AHA Guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol,2013,62(16):e147-e239.

[3]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]．中华心血管病杂志,2018,46(10):760-789．

[4]Benjamin EJ,Muntner P, Alonso A,et al. Heart disease and stroke statistics-2019 update:a report from the American Heart Association[J]. Circulation,2019,139(10):e56-e528.

[5]中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2019摘要[J]. 中国循环杂志,2020,35(9):833-854.

[6]Lund LH,Claggett B,Liu J,et al. Heart failure with mid-range ejection fraction in CHARM:characteristics,outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail,2018,20(8):1230-1239.

[7]Tsuji K,Sakata Y,Nochioka K,et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 Study[J]. Eur J Heart Fail,2017,19(10):1258-1269.

[8]Koh AS,Tay WT,Teng THK,et al. A comprehensive populationbased characterization of heart failure with midrange ejection fraction[J]. Eur J Heart Fail,2017,19(12):1624-1634.

[9]Chioncel O,Lainscak M,Seferovic PM,et al. Epidemiology and oneyear outcomes in patients with chronic heart failure and preserved,midrange and reduced ejection fraction:an analysis of the ESC Heart Failure LongTerm Registry[J]. Eur J Heart Fail,2017,19(12):15741585.

[10]王华,李莹莹,柴坷,等．中国住院心力衰竭患者流行病学及治疗现状[J]. 中华心血管病杂志,2019,47(11):865-874.

[11]Lyu S,Yu L,Tan H,et al. Clinical characteristics and prognosis of heart failure with midrange ejection fraction:insights from a multi-centre registry study in China[J]. BMC Cardiovasc Disord,2019,19(1):209.

[12]Cho JH,Choe WS,Cho HJ,et al. Comparison of characteristics and 3-year outcomes in patients with acute heart failure with preserved,mid-range,and reduced ejection fraction[J]. Circ J,2019,83(2):347-356.

[13]Abdul-Rahim AH,Shen L,Rush CJ,et al. Effect of digoxin in patients with heart failure and mid-range(borderline) left ventricular ejection fraction[J]. Eur J Heart Fail,2018,20(7):1139-1145.

[14]Brann A,Janvanishstaporn S,Greenberg B,et al. Association of prior left ventricular ejection fraction with clinical outcomes in patients with heart failure with midrange ejection fraction[J]. JAMA Cardiol,2020,5(9):1027-1035.

[15]Rastogi A,Novak E,Platts AE,et al. Epidemiology,pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction[J]. Eur J Heart Fail,2017,19(12):1597-1605.

[16]Solomon SD,Claggett B,Lewis EF,et al. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction[J]. Eur Heart J,2016,37(5):455-462.

[17]Lauritsen J,Gustafsson F,Abdulla J,et al. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction:a systematic review and meta-analysis[J]. ESC Heart Fail,2018,5(4):685-694.

[18]Farré N,Lupon J,Roig E,et al. Clinical characteristics,oneyear change in ejection fraction and longterm outcomes in patients with heart failure with midrange ejection fraction:a multicentre prospective observational study in Catalonia(Spain)[J]. BMJ Open,2017,7(12):e018719.

[19] Nadruz W Jr,West E,Santos M,et al. Heart failure and midrange ejection fraction implications of recovered ejection fraction for exercise tolerance and outcomes[J]. Circ Heart Fail,2016,9(4):e002826.

[20]Magr? D,Piepoli M,Corr? U,et al. Cardiovascular death risk in recovered mid-range ejection fraction heart failure:insights from cardiopulmonary exercise test[J]. J Card Fail,2020,26(11):932-943.

[21]Gu J,Yin ZF,Zhang HL,et al. Characteristics and outcomes of transitions among heart failure categories:a prospective observational cohort study[J]. ESC Heart Fail,2020,7(2):616-625.

[22]Colvin MM,Sutton NR. Left ventricular recovery in young patients with myocardial infarction:how much is enough?[J]. J Am Coll Cardiol,2020,75(22):2816-2818.

[23]Park JJ,Park CS,Mebazaa A,et al. Characteristics and outcomes of HFpEF with declining ejection fraction[J]. Clin Res Cardiol,2020,109(2):225-234.

[24]Yoshihisa A,Sato Y,Kanno Y,et al. Prognostic impacts of changes in left ventricular ejection fraction in heart failure patients with preserved left ventricular ejection fraction[J]. Open Heart,2020,7(1):e001112.

[25]Cleland JGF,Bunting KV,Flather MD,et al. Beta-blockers for heart failure with reduced,mid-range,and preserved ejection fraction:an individual patient-level analysis of double-blind randomized trials[J]. Eur Heart J,2018,39(1):26-35.

[26]Fu EL,Uijl A,Dekker FW,et al. Association between β-blocker use and mortality/morbidity in patients with heart failure with reduced,midrange,and preserved ejection fraction and advanced chronic kidney disease[J]. Circ Heart Fail,2020,13(11):e007180.

[27]Beldhuis IE,Myhre PL,Bristow M,et al. Spironolactone in patients with heart?failure,preserved ejection fraction,and worsening renal function[J]. J Am Coll Cardiol,2021,77(9):1211-1221.

[28]Mc Causland FR,Lefkowitz MP,Claggett B,et al. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction[J]. Circulation,2020, 142(13):1236-1245.

[29]Solomon SD,Vaduganathan M,Claggett BL,et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure[J]. Circulation,2020,141(5):352-361.

[30]Lund LH,Claggett B,Liu J,et al. Heart failure with mid-range ejection fraction in CHARM:characteristics,outcomes and effect of candesartan across the entire ejection fraction spectrum[J]. Eur J Heart Fail,2018,20(8):1230-1239.

相似文献/References:

[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
　DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(11):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
　LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(11):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
　ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(11):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
　LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(11):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
　KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(11):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
　SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(11):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
　XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(11):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
　GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(11):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
　HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(11):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
　WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(11):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]

更新日期/Last Update: 2021-12-06